Trial record 1 of 1 for:
GEMCAD 17-01
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03751176 |
|
Recruitment Status :
Recruiting
First Posted : November 23, 2018
Last Update Posted : February 19, 2020
|
Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo
Collaborators:
Amgen
Pivotal S.L.
Information provided by (Responsible Party):
Grupo Espanol Multidisciplinario del Cancer Digestivo
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | November 30, 2020 |
| Estimated Study Completion Date : | November 30, 2022 |